Johnson & Johnson (JNJ) Stock Analysis 2026

Johnson & Johnson is one of the world's largest healthcare companies, operating across two segments after spinning off its consumer health division (Kenvue) in 2023. The remaining company focuses on Innovative Medicine (pharmaceuticals — ~55% of revenue) and MedTech (medical devices — ~45%). J&J's pharmaceutical portfolio includes blockbusters like Darzalex (multiple myeloma), Stelara (immunology), Tremfya (psoriasis), and Erleada (prostate cancer). The MedTech division is a leader in orthopedics, surgery, and interventional solutions.

This chart shows how Johnson & Johnson's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Johnson & Johnson trades at a trailing P/E of 31.06x, generates $16.89B in free cash flow, runs a debt/equity ratio of 57.71, and converts shareholder equity into profit at a 25.7% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

23 analysts covering Johnson & Johnson currently lean toward a Hold rating, with a mean 12-month price target of $272.50 (+0.9% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate JNJ's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

JNJ is currently in a golden cross pattern, trading above its 50-day average of $258.89 and above its 200-day average of $234.25. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

JNJ's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.